Gyre Therapeutics, Inc.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Mar 2026 | Mar 2026 | Dec 2025 | Oct 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $29.1M | — | $22.5M | — | — | — | $30.6M |
| Cost of Revenue | — | $2.2M | — | $1.2M | — | — | — | $1.6M |
| Gross Profit | — | $26.9M | — | $21.3M | — | — | — | $28.9M |
| Gross Margin | — | 92.4% | — | 94.6% | — | — | — | 94.7% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | $6.7M | — | — | — | $2.4M |
| SG&A Expense | — | $7.9M | — | $7.2M | — | — | — | $4.3M |
| Operating Income | — | $-14.4M | — | $-9.4M | — | — | — | $6.9M |
| Operating Margin | — | -49.3% | — | -41.5% | — | — | — | 22.7% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-14.4M | — | $-9.2M | — | — | — | $7.6M |
| Income Tax Expense | — | $-164.0K | — | $621.0K | — | — | — | $1.7M |
| Net Income | — | $-14.3M | — | $-18.6M | — | — | — | $5.9M |
| Net Margin | — | -49.0% | — | -82.5% | — | — | — | 19.4% |
| EPS (Basic) | — | $-0.12 | — | $-0.10 | — | — | — | $0.04 |
| EPS (Diluted) | — | $-0.12 | — | $-0.10 | — | — | — | $0.03 |
| Shares Outstanding (Basic) | 111.5M | 100.6M | 97.0M | 91.3M | 97.0M | 91.3M | 96.3M | 90.9M |
| Shares Outstanding (Diluted) | 111.5M | 100.6M | 97.0M | 91.3M | 97.0M | 91.3M | 96.3M | 104.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |